Venn Life Sciences Grows CRO Business in Europe - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Venn Life Sciences Grows CRO Business in Europe

Source: Applied Clinical Trials

Venn Life Sciences, a CRO providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the recent acquisition of two European CROs. Venn acquired German CRO CRM clinical trials and Medevol Clinical Services in the UK. Venn has operations in France, Ireland, the Netherlands, Russia, the UK and a branch office in Switzerland. It also has a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe.

Founded in 1996, CRM is a full-service CRO based in Rheinbach, Germany, specializing in Phases II-IV. CRM has extensive experience in dermatology, pneumology and urology, and its suite of services include initial and ongoing training for study nurses, investigators and trial teams in the areas of quality, planning andmonitoring of clinical studies.

The second acquisition is Medevol, a CRO in the UK clinical trials market since 2001, conducting full-service studies for global pharmaceutical and biotechnology companies across Phases II - IV. With extensive therapeutic experience across a broad range of indications, Medevol also provide contract staffing solutions. The company is based in Belfast.

You can read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
88%
Borrow lightly from EMA's pathway program?
4%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here